NextCure director granted 2,340 stock options

NextCure, Inc. director Anne Elizabeth Borgman reported a grant of stock options covering 2,340 shares of common stock at an exercise price of $2.02 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NextCure, Inc. director Anne Elizabeth Borgman reported a grant of stock options covering 2,340 shares of common stock at an exercise price of $2.02 per share. The option vests in full on the earlier of June 18, 2027 and the 2027 Annual Meeting of Stockholders and expires on June 17, 2036. Following this grant, she holds 2,340 options directly.

Insider Trade Summary

Grant/Award: 2,340 shares

Grant/Award 1 txn

Insider Borgman Anne Elizabeth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,340	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,340 contracts (Direct)

Footnotes (1)

F1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

Key Figures

Option grant size: 2,340 options Exercise price: $2.02 per share Underlying shares: 2,340 shares +3 more

6 metrics

Option grant size 2,340 options Stock Option (Right to Buy) awarded to director

Exercise price $2.02 per share Conversion or exercise price of stock option

Underlying shares 2,340 shares Common Stock underlying the option award

Post-grant holdings 2,340 options Total options held following this transaction

Vesting date trigger June 18, 2027 Full vesting on earlier of this date or 2027 Annual Meeting

Option expiration June 17, 2036 Expiration date of the stock option award

Key Terms

Stock Option (Right to Buy), Common Stock, Grant, award, or other acquisition, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Annual Meeting of Stockholders financial

"the date of the 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NextCure (NXTC) director Anne Borgman report?

Anne Elizabeth Borgman reported receiving a stock option grant covering 2,340 shares of NextCure common stock. The options were awarded as a compensation grant and are exercisable into common shares at a fixed price if vesting and other terms are met.

How many NextCure (NXTC) shares are covered by Anne Borgman’s new options?

The reported stock option award covers 2,340 underlying shares of NextCure common stock. These options give her the right to buy that number of shares at a preset exercise price, subject to vesting and the option’s expiration schedule.

What is the exercise price of Anne Borgman’s NextCure (NXTC) stock options?

The options have an exercise price of $2.02 per share of NextCure common stock. This means she can purchase the underlying shares at $2.02, once the options have vested and before they expire in 2036, subject to the award terms.

When do Anne Borgman’s NextCure (NXTC) options vest?

The option vests in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders. Full vesting on one of these dates allows her to exercise the entire 2,340-share award afterward, before expiration.

When do Anne Borgman’s NextCure (NXTC) stock options expire?

The stock options reported by Anne Borgman expire on June 17, 2036. After that expiration date, any unexercised portion of the 2,340-share award can no longer be converted into common stock, even if the options had previously vested in full.

How many NextCure (NXTC) options does Anne Borgman hold after this grant?

Following this transaction, Anne Borgman is reported to hold 2,340 stock options directly. This total matches the size of the newly granted award, indicating this filing reflects a single compensation-related option grant rather than multiple separate awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:14 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgman Anne Elizabeth

(Last)

(First)

(Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE

MARYLAND

20705

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.02	06/18/2026		A		2,340		⁽¹⁾	06/17/2036	Common Stock	2,340	$0	2,340	D

Explanation of Responses:

1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for Anne Borgman	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR